Clinigen Signs Managed Access Programme With Sunesis For Vosaroxin

LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Thursday said its managed-access division has partnered with Sunesis Pharmaceuticals Inc, a US-based biopharmaceutical company, to handle its compassionate-use programme for vosaroxin.

Vosaroxin is an investigational treatment for patients with relapsed or refractory acute myeloid leukaemia.

Compassionate-use programmes are put in place to provide access to medicines for people who have serious, or immediately life-threatening diseases and for whom no alternative treatment options are available.

No financial details on the contract were disclosed.

Clinigen shares were up 1.5% to 693.00 pence on Thursday.

By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance

Copyright 2015 Alliance News Limited. All Rights Reserved.